128
Views
5
CrossRef citations to date
0
Altmetric
Review

Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients

, &
Pages 1-19 | Published online: 16 Dec 2013

Figures & data

Table 1 Treatment options, current, and future biomarkers in different subgroups of breast cancer

Figure 1 Schematic representation of the main targeted pathways and their inhibitory drugs in breast cancer treatment.

Note: Schematic based on a knowledge of the underlying genetic changes and downstream biological consequences.
Abbreviations: E2, estradiol; AI, aromatase inhibitors; EGF, epidermal growth factor; HER, human epidermal growth factor; ER, estrogen receptor; PTEN, phosphatase and tensin homolog; PI3Ki, PI3 kinase inhibitors (ie, BKM120, GDC0941, XL147, BYL719, BEZ235); TK, tyrosine kinase; T-DM1, trastuzumab emtansine; AKT, serine/threonine-specific protein kinase; mTOR, mammalian target of rapamycin; RAS, reticular activating system; MEK, mitogen-activated extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; FGFRi, fibroblast growth factor receptor inhibitors (ie, dovitinib, intedanib, brivanib).
Figure 1 Schematic representation of the main targeted pathways and their inhibitory drugs in breast cancer treatment.